IPSS-R stands for the Revised International Prognostic Scoring System. It is a clinical scoring tool used mainly in myelodysplastic syndromes (MDS), a group of bone marrow blood cancers. IPSS-R helps clinicians estimate disease risk and likely disease behavior over time. It is commonly used at or near diagnosis to support treatment planning and follow-up discussions.

IPSS stands for the International Prognostic Scoring System. It is a clinical scoring tool used to estimate risk in myelodysplastic syndromes (MDS), a group of bone marrow disorders that can behave like cancers. IPSS helps clinicians describe how aggressive the disease appears at diagnosis. It is commonly used in hematology-oncology to guide discussion, monitoring intensity, and treatment planning.

R-ISS is the Revised International Staging System used for multiple myeloma. It groups myeloma into stages based on lab tests and specific genetic risk features. Clinicians use it to estimate prognosis and to communicate disease risk in a consistent way. It is commonly used in hematology-oncology clinics and in myeloma clinical trials.

ISS staging is a clinical staging system most commonly used for multiple myeloma. It groups myeloma into broad risk categories using simple blood test results. It helps clinicians describe disease severity in a standardized way. It is often used at diagnosis and when discussing prognosis and treatment planning.

Lugano classification is a standardized way to describe the stage and treatment response of lymphoma. It helps clinicians use the same language when reporting where lymphoma is in the body and how it is changing over time. It is commonly used in Hodgkin lymphoma and many types of non-Hodgkin lymphoma. It is most often applied using imaging such as PET/CT and CT, along with biopsy and clinical findings.

Ann Arbor staging is a clinical system used to describe how far certain lymphomas have spread in the body. It groups disease by which lymph node regions are involved and whether organs outside the lymph system are affected. It is most commonly used for Hodgkin lymphoma and is also used in selected non-Hodgkin lymphomas. Staging helps clinicians communicate clearly and plan care in a consistent way.

FIGO staging is a standardized way to describe how far certain gynecologic cancers have spread. It is published by the International Federation of Gynecology and Obstetrics (FIGO). Clinicians use it most often for cancers of the cervix, uterus (endometrium), ovary/fallopian tube, vulva, and vagina. It helps teams speak a common “stage language” when planning care and discussing outcomes.

pM is a staging term used in oncology within the TNM cancer staging system. It describes whether **distant metastasis** (spread to organs or tissues away from the primary tumor) has been confirmed by **pathology**. In plain language, pM reflects “metastasis proven by a tissue sample” rather than by imaging alone. It is commonly used in pathology reports and staging summaries for many solid tumors, though details vary by cancer type and staging rules.

cM is a cancer staging term that describes **clinical evidence of distant metastasis**. It is part of the TNM system used to summarize how far a cancer has spread. Clinicians assign cM using information from exams, imaging, and selected tests before definitive treatment. You may see cM in pathology and radiology reports, clinic notes, tumor board summaries, and treatment plans.

pN is a cancer staging term that describes whether cancer has spread to **regional lymph nodes** based on **pathology**. It is part of the TNM system used in many solid tumors, where “p” means **pathologic** (confirmed under a microscope). pN is usually assigned after lymph nodes are removed or sampled during surgery and examined by a pathologist. It helps clinicians communicate stage and plan care using a standardized, widely recognized format.